# To Evaluate the Safety, Tolerability, Pharmacokinetics and the Effect of Food on the Hemay5259 Sustained-release Tablets in Healthy Subjects.

> **NCT07703904** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hemay Pharmaceutical PTY. LTD.** · enrollment: 32 (estimated)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Hemay5259 group 1
- **DRUG:** placebo group 1
- **DRUG:** Hemay5259 group 2
- **DRUG:** Placebo group 2

## Key facts

- **NCT ID:** NCT07703904
- **Lead sponsor:** Hemay Pharmaceutical PTY. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703904, "To Evaluate the Safety, Tolerability, Pharmacokinetics and the Effect of Food on the Hemay5259 Sustained-release Tablets in Healthy Subjects.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*